Please login to the form below

Not currently logged in
Email:
Password:

Almirall appoints first woman to the board

Karin Louise Dorrepaal will serve as an independent board member

Spanish pharmaceutical company Almirall has picked Karin Louise Dorrepaal to sit on its board of directors as an independent board member.

She is the first woman to join the Barcelona-based company's ten member board and has gained extensive international experience in the pharmaceutical sector during her 25 year career.

This includes six years serving as director of global business unit diagnostic imaging and supply chain and procurement at Bayer Pharma and sitting on the board of Schering for two years.

Dorrepaal currently holds non-executive positions in healthcare sector and consultancy companies.

Earlier this month, she was appointed to the supervisory board of German specialty pharma company Paion, where she replaced Grünenthal chief executive Harald Stock. 

Dorrepaal's appointment to the Almirall board will take effect from January 1, 2013, and will be ratified at the company's next annual general meeting.

23rd November 2012

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics